Cencora, Inc. (COR) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-05-06

Key Insights

Cencora announced Q3 fiscal 2026 earnings (quarter ended March 31, 2026) via news release, indicating the company continues regular quarterly reporting and financial disclosure obligations.
The company maintains investment-grade debt with two active senior note tranches (2.875% due 2028 and 3.625% due 2032), both trading on NYSE, reflecting stable long-term financing structure.
A conference call and webcast were scheduled for 8:30 a.m. ET on May 6, 2026, with presentation slides available on investor.cencora.com, providing stakeholders access to management commentary on quarterly performance and forward-looking guidance.

Want the newest filings?

This analysis covers the filing from 2026-05-06. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-03-06

Cencora, Inc. (COR) held its 2026 Annual Meeting of Shareholders on March 5, 2026, where shareholders voted on the election of directors, the fiscal 2025 compensation of the company's named executive officers, and the ratification of Ernst & Young LLP as the company's independent registered public accounting firm for fiscal 2026.
The election of the eleven directors nominated by the company was approved by the shareholders, with the majority of votes cast in favor of each nominee.
The shareholders approved, on an advisory basis, the fiscal 2025 compensation of the company's named executive officers, and also ratified the appointment of Ernst & Young LLP as the company's independent registered public accounting firm for fiscal 2026.

Filed: 2026-02-18

Cencora, Inc. has agreed to merge its animal health business MWI with Covetrus, Inc. for an enterprise value of $3.5 billion, which will provide the company with significant cash and equity consideration.
The transaction is subject to regulatory approvals and is expected to close, at which point Cencora will hold a 34.3% ownership stake in the combined entity.
The merger with Covetrus represents a strategic shift for Cencora as it focuses on its core business and unlocks value from the MWI division.

Filed: 2026-02-13

Cencora, Inc. completed a $3 billion bond offering with various maturities and coupon rates, signaling their need for additional capital.
The company issued new senior notes across a range of maturities from 2029 to 2056, indicating potential long-term growth plans or refinancing needs.
The bond offering provides Cencora with enhanced financial flexibility, but the high coupon rates may impact their future profitability and cash flow.

Filed: 2026-02-11

Cencora, Inc. issued $3 billion in new senior notes across maturities from 2029 to 2056, indicating the company is taking advantage of favorable market conditions to refinance existing debt.
The net proceeds from the note offering will be used to repay the company's $3 billion 364-Day Term Loan Facility, reducing interest expense and extending the debt maturity profile.
Several of the underwriters for this note offering have long-standing relationships with Cencora, having served as underwriters for past note issuances and in various roles for the company's credit facilities.

Filed: 2026-02-10

Cencora, Inc. has acquired Retina Consultants of America (RCA), a strategic move that may expand its medical services offerings.
The company has issued $5,000 million in senior notes due in 2028 and 2032, potentially indicating plans for future growth and expansion.
The company's customer concentration risk is notable, with two major customers (Walgreens and Evernorth Health Services) accounting for a significant portion of sales and accounts receivable.

Filed: 2026-02-04

Cencora, Inc. announced the acquisition of a majority stake in OneOncology, a physician-led national platform focused on oncology, for $4.6 billion. This strategic move will expand Cencora's presence in the U.S. healthcare solutions segment.
The company reported its Q4 2025 earnings, providing an update on its financial performance for the quarter. Investors will be interested in analyzing the earnings results and any guidance provided for the upcoming fiscal year.
Cencora has issued new debt financing to fund the OneOncology acquisition, which could impact the company's leverage and capital structure going forward.

Filed: 2026-01-22

Cencora, Inc. appointed a new director, Ellen G. Cooper, to its Board of Directors, expanding the board from 10 to 11 members.
The company issued new 2.875% senior notes due 2028 and 3.625% senior notes due 2032, which will be traded on the New York Stock Exchange.
There are no indications of any family relationships between the new director and the company's executives, or any related party transactions requiring disclosure.

Filed: 2026-01-16

Cencora, Inc. increased the aggregate amount of commitments under its Revolving Credit Agreement by $1.0 billion to $5.5 billion, providing additional financial flexibility.
The company entered into a $1.5 billion Term Credit Agreement and a $3.0 billion 364-Day Term Credit Facility to fund the acquisition of the majority stake in OneOncology, indicating its strategic focus on growing its oncology business.
The new credit facilities include financial covenants and terms similar to the company's existing Revolving Credit Agreement, suggesting a continuity in its debt management approach.

Other reports for Cencora, Inc.

Quarterly Report Insider Trading

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.